计算溶液所需的质量、体积或浓度。
| 活性类型 | Relation | Activity value | Units | Action Type | 期刊 | PubMed Id | doi | Assay Aladdin ID |
|---|
提供 ≥99% 纯度,适用于对基线干扰要求严格的色谱和分析工作流程。
2-8°C储存,避光,干燥。低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
K134 is a phosphodiesterase 3 ( PDE3 ) inhibitor. The IC 50 s of K134 toward PDE3A , PDE3B , PDE5 , PDE2 and PDE4 are 0.1, 0.28, 12.1, >300 and >300 µM, respectively.
In Vitro
K134 (K-134) inhibits rat platelet aggregation induced by collagen and ADP in a dose-dependent manner in vitro. The half-maximal (50%) inhibitory concentration (IC 50 ) values of K134 are 2.5 µM and 3.2 µM, respectively. In vitro experiments, K134 also inhibits mouse platelet aggregation induced by collagen and ADP in a dose-dependent manner, and the IC 50 s are 5.5 µM and 6.7 µM, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
K134 (K-134) significantly prolongs middle cerebral artery (MCA) occlusion time at doses >10 mg/kg, and reduces cerebral infarct size at 30 mg/kg in the stroke model (n = 12, 87.5±5.6 vs. 126.8±7.5 mm 3 , P<0.01), indicating its potent antithrombotic effect. The overall bleeding risk of K134 is assessed in general in mice. Single oral administration of K134 does not prolong bleeding time at a dose of 30 mg/kg compared to control (106±5 vs. 110±5 s, not significant). Moreover, a sufficiently high enough plasma concentration of K134 (13.6±2.3 µM) is detected to inhibit platelet aggregation at 10 min after single administration in mice at a dose of 30 mg/kg, which is the same time point as the above test of bleeding time. Next, the effects of PDE3 inhibitors on thrombus formation are also investigated in an arteriovenous shunt model in rats. K134 significantly reduces the incidence of occlusive shunt thrombi at doses above 10 mg/kg (half-maximal effective dose: ED 50 =11 mg/kg). The plasma concentration of K134 is 0.43±0.08 µM (C max ) at a dose of 10 mg/kg . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Form:Solid
IC50& Target:IC50: 0.1 µM (PDE3A), 0.28 µM (PDE3B), 12.1 μM (PDE5)
分类树(Taxonomy Tree)
| 界(kingdom) | 有机化合物 |
|---|---|
| 超类(Superclass) | 有机杂环化合物 |
| 类(Class) | 喹啉及其衍生物 |
| 亚类(Subclass) | 喹诺酮类及其衍生物 |
| 中间层级节点(Intermediate Tree Nodes) | 暂无 |
| 直接上位类(Direct Parent) | 氢化喹诺酮类药物 |
| 其他上位类(Alternative Parents) | 氢化喹啉 吡啶酮类 环己醇 烷基芳基醚 苯类化合物 杂芳族化合物 尿素 内酰胺类 环状醇及其衍生物 氮杂环化合物 有机光子化合物 有机氮化合物 有机氧化物 碳氢化合物衍生物 羰基化合物 |
| 分子骨架(Molecular Framework) | 芳香族杂多环化合物 |
| 取代基(Substituents) | 羟基苯甲酸酯 - 芳基醚 - 芳香族杂多环化合物 - 氮杂环 - 苯基化合物 - 碳酸衍生物 - 羰基 - 环醇 - 环己醇 - 二氢喹啉 - 二氢喹啉酮 - 乙醚 - 杂芳香族化合物 - 烃衍生物 - 肟 - 有机硝基化合物 - 有机氧化物 - 有机氧化合物 - 有机氮化合物 - 有机氧化合物 - 有机氮化合物 - 吡啶 - 吡啶酮 - 醛基 - 脲 |
| 描述(Description) | 该化合物属于有机化合物中称为羟喹诺酮类的一类。这类化合物含有一个带酮基团的氢化喹啉。 |
| 外部描述符(External Descriptors) | 暂无 |
| ALogP | 2.2 |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|